Compare · CTY vs NVO
CTY vs NVO
Side-by-side comparison of City Therapeutics Inc. (CTY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $180.22B, about 204.6x CTY ($880.8M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 8 for CTY).
- NVO has more recent analyst coverage (25 ratings vs 3 for CTY).
- Company
- City Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $880.8M
- $180.22B
- 1M return
- -
- +5.96%
- 1Y return
- -
- -14.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 8
- 9
- Recent ratings
- 3
- 25
City Therapeutics Inc.
City Therapeutics is a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, with the aim of delivering meaningful and durable benefits for patients in need. City's lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases. The City Platform is the engine behind every therapeutic the company develops and integrates deep expertise in trigger engineering, including proprietary cityRNA triggers designed to address limitations of conventional RNAi approaches, tissue-selective delivery, and genetics-driven target selection.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CTY
- Oppenheimer initiated coverage on City Therapeutics with a new price target
- Stifel initiated coverage on City Therapeutics with a new price target
- Jefferies initiated coverage on City Therapeutics with a new price target
- City Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease
- SEC Form SCHEDULE 13G filed by City Therapeutics Inc.
- Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
- City Therapeutics to Present at Upcoming November Investor Conferences
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S